{"eventGroups":[{"description":"This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.","id":"EG000","otherNumAffected":3,"otherNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"title":"Lenalidomide and Rituximab"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Hemoglobin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"PT INR"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3,"numEvents":2}],"term":"Leukocytes (total WBC)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Lymphopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3,"numEvents":2}],"term":"Neuropathy: sensory"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":3,"numEvents":3}],"term":"Neutrophils/granulocytes"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTC-3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1}],"term":"Pulmonary/upper respiratory"}]}